25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Capricor Therapeutics Inc
Buy, Hold or Sell?

Let's analyze Capricor together

I guess you are interested in Capricor Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Capricor Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Capricor Therapeutics Inc

I send you an email if I find something interesting about Capricor Therapeutics Inc.

1. Quick Overview

1.1. Quick analysis of Capricor (30 sec.)










1.2. What can you expect buying and holding a share of Capricor? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$1.50
Expected worth in 1 year
$3.04
How sure are you?
32.5%

+ What do you gain per year?

Total Gains per Share
$1.54
Return On Investment
10.6%

For what price can you sell your share?

Current Price per Share
$14.53
Expected price per share
$12.25 - $16.77
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Capricor (5 min.)




Live pricePrice per Share (EOD)
$14.53
Intrinsic Value Per Share
$-11.54 - $-7.16
Total Value Per Share
$-10.04 - $-5.66

2.2. Growth of Capricor (5 min.)




Is Capricor growing?

Current yearPrevious yearGrowGrow %
How rich?$68.2m$4.7m$25.4m84.3%

How much money is Capricor making?

Current yearPrevious yearGrowGrow %
Making money-$8.5m$96.7m-$105.3m-1,234.7%
Net Profit Margin-259.5%3,143.6%--

How much money comes from the company's main activities?

2.3. Financial Health of Capricor (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#408 / 932

Most Revenue
#338 / 932

Most Profit
#492 / 932

Most Efficient
#546 / 932
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Capricor?

Welcome investor! Capricor's management wants to use your money to grow the business. In return you get a share of Capricor.

First you should know what it really means to hold a share of Capricor. And how you can make/lose money.

Speculation

The Price per Share of Capricor is $14.53. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Capricor.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Capricor, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $1.50. Based on the TTM, the Book Value Change Per Share is $0.39 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.09 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Capricor.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.28-1.9%-0.19-1.3%-0.16-1.1%-0.13-0.9%-0.09-0.7%
Usd Book Value Change Per Share1.258.6%0.392.7%-0.09-0.7%0.070.5%0.040.3%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share1.258.6%0.392.7%-0.09-0.7%0.070.5%0.040.3%
Usd Price Per Share15.21-7.92-4.07-4.67-3.77-
Price to Earnings Ratio-13.77--24.88--6.33--12.09--11.25-
Price-to-Total Gains Ratio12.18--21.02--44.89--31.67--82.60-
Price to Book Ratio10.13-13.89-9.60-9.14-78.38-
Price-to-Total Gains Ratio12.18--21.02--44.89--31.67--82.60-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share14.53
Number of shares68
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.390.07
Usd Total Gains Per Share0.390.07
Gains per Quarter (68 shares)26.194.84
Gains per Year (68 shares)104.7619.35
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10105950199
2021020003928
3031430505847
4041941007766
5052451509785
606296200116104
707337250135123
808388300155142
909439350174161
100104810400194180

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%1.039.00.02.5%1.091.00.01.1%
Book Value Change Per Share2.02.00.050.0%2.010.00.016.7%7.013.00.035.0%13.027.00.032.5%19.070.03.020.7%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.092.00.0%
Total Gains per Share2.02.00.050.0%2.010.00.016.7%7.013.00.035.0%13.027.00.032.5%19.070.03.020.7%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Capricor Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--1.2480.385+224%-0.095+108%0.071+1655%0.040+3022%
Book Value Per Share--1.5010.664+126%0.104+1342%0.487+208%0.261+476%
Current Ratio--0.0041.143-100%1.269-100%6.589-100%5.471-100%
Debt To Asset Ratio--0.2660.552-52%0.910-71%0.489-46%0.683-61%
Debt To Equity Ratio--0.3621.493-76%6.694-95%2.078-83%14.067-97%
Dividend Per Share----0%-0%-0%-0%
Enterprise Value--751939149.000378717076.000+99%181243009.250+315%228527860.100+229%179013679.594+320%
Eps---0.276-0.188-32%-0.161-42%-0.132-52%-0.095-66%
Ev To Ebitda Ratio---14.862-21.423+44%-5.709-62%-11.862-20%-11.423-23%
Ev To Sales Ratio--83.11929.448+182%20.471+306%infnan%infnan%
Free Cash Flow Per Share---0.257-0.211-18%-0.129-50%-0.091-65%-0.115-55%
Free Cash Flow To Equity Per Share--1.2230.311+294%-0.099+108%0.086+1327%11.915-90%
Gross Profit Margin--276.578243.186+14%1.000+27558%49.437+459%25.219+997%
Intrinsic Value_10Y_max---7.156--------
Intrinsic Value_10Y_min---11.544--------
Intrinsic Value_1Y_max---0.469--------
Intrinsic Value_1Y_min---0.582--------
Intrinsic Value_3Y_max---1.597--------
Intrinsic Value_3Y_min---2.256--------
Intrinsic Value_5Y_max---2.955--------
Intrinsic Value_5Y_min---4.475--------
Market Cap660677647.000-5%691597179.000359894258.500+92%185062493.000+274%212298963.100+226%171401516.244+303%
Net Profit Margin---5.552-2.595-53%31.436-118%-21.496+287%-13.218+138%
Operating Margin---5.752-2.717-53%-3.563-38%-29.015+404%-17.764+209%
Operating Ratio---997.469-247.374-75%5.281-18989%-20.436-98%-3.503-100%
Pb Ratio9.678-5%10.13113.893-27%9.600+6%9.135+11%78.382-87%
Pe Ratio-13.154+4%-13.769-24.880+81%-6.329-54%-12.088-12%-11.248-18%
Price Per Share14.530-5%15.2107.915+92%4.070+274%4.669+226%3.770+303%
Price To Free Cash Flow Ratio-14.115+4%-14.776-15.901+8%-0.597-96%-9.965-33%-11.051-25%
Price To Total Gains Ratio11.639-5%12.184-21.021+273%-44.890+468%-31.673+360%-82.605+778%
Quick Ratio--0.0051.843-100%1.895-100%7.520-100%6.729-100%
Return On Assets---0.135-0.158+17%1.775-108%0.252-154%0.033-511%
Return On Equity---0.184-0.426+132%15.622-101%2.914-106%-1.398+660%
Total Gains Per Share--1.2480.385+224%-0.095+108%0.071+1655%0.040+3022%
Usd Book Value--68264959.00030200917.500+126%4733962.500+1342%22154810.050+208%11852037.775+476%
Usd Book Value Change Per Share--1.2480.385+224%-0.095+108%0.071+1655%0.040+3022%
Usd Book Value Per Share--1.5010.664+126%0.104+1342%0.487+208%0.261+476%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Enterprise Value--751939149.000378717076.000+99%181243009.250+315%228527860.100+229%179013679.594+320%
Usd Eps---0.276-0.188-32%-0.161-42%-0.132-52%-0.095-66%
Usd Free Cash Flow---11701504.000-9581735.000-18%-5861339.000-50%-4118821.650-65%-5223448.050-55%
Usd Free Cash Flow Per Share---0.257-0.211-18%-0.129-50%-0.091-65%-0.115-55%
Usd Free Cash Flow To Equity Per Share--1.2230.311+294%-0.099+108%0.086+1327%11.915-90%
Usd Market Cap660677647.000-5%691597179.000359894258.500+92%185062493.000+274%212298963.100+226%171401516.244+303%
Usd Price Per Share14.530-5%15.2107.915+92%4.070+274%4.669+226%3.770+303%
Usd Profit---12556728.000-8528168.000-32%96772419.463-113%14843091.893-185%6108439.921-306%
Usd Revenue--2261642.0005807011.500-61%3511832.000-36%14214864.500-84%7466240.575-70%
Usd Total Gains Per Share--1.2480.385+224%-0.095+108%0.071+1655%0.040+3022%
 EOD+2 -6MRQTTM+24 -14YOY+22 -165Y+23 -1410Y+23 -14

3.3 Fundamental Score

Let's check the fundamental score of Capricor Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-13.154
Price to Book Ratio (EOD)Between0-19.678
Net Profit Margin (MRQ)Greater than0-5.552
Operating Margin (MRQ)Greater than0-5.752
Quick Ratio (MRQ)Greater than10.005
Current Ratio (MRQ)Greater than10.004
Debt to Asset Ratio (MRQ)Less than10.266
Debt to Equity Ratio (MRQ)Less than10.362
Return on Equity (MRQ)Greater than0.15-0.184
Return on Assets (MRQ)Greater than0.05-0.135
Total2/10 (20.0%)

3.4 Technical Score

Let's check the technical score of Capricor Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5051.587
Ma 20Greater thanMa 5014.009
Ma 50Greater thanMa 10015.505
Ma 100Greater thanMa 20014.507
OpenGreater thanClose14.620
Total4/5 (80.0%)

4. In-depth Analysis

4.1 About Capricor Therapeutics Inc

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment of duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs. The company's lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase 3 clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD). It also focused on developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases. In addition, the company develops CAP-2003, under pre-clinical development for the treatment of trauma related injuries and conditions. It has collaboration and distribution agreement with Nippon Shinyaku Co. Ltd., collaboration agreement with National Institute of Allergy and Infectious Diseases, license agreements with the Johns Hopkins University and Cedars-Sinai Medical Center, as well as cell line license agreement with Life Technologies Corporation. The company was founded in 2005 and is headquartered in San Diego, California.

Fundamental data was last updated by Penke on 2025-01-16 15:13:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Capricor earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Capricor to the Biotechnology industry mean.
  • A Net Profit Margin of -555.2% means that $-5.55 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Capricor Therapeutics Inc:

  • The MRQ is -555.2%. The company is making a huge loss. -2
  • The TTM is -259.5%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-555.2%TTM-259.5%-295.7%
TTM-259.5%YOY3,143.6%-3,403.1%
TTM-259.5%5Y-2,149.6%+1,890.1%
5Y-2,149.6%10Y-1,321.8%-827.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-555.2%-104.8%-450.4%
TTM-259.5%-211.9%-47.6%
YOY3,143.6%-209.8%+3,353.4%
5Y-2,149.6%-354.1%-1,795.5%
10Y-1,321.8%-488.5%-833.3%
4.3.1.2. Return on Assets

Shows how efficient Capricor is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Capricor to the Biotechnology industry mean.
  • -13.5% Return on Assets means that Capricor generated $-0.14 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Capricor Therapeutics Inc:

  • The MRQ is -13.5%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -15.8%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-13.5%TTM-15.8%+2.3%
TTM-15.8%YOY177.5%-193.3%
TTM-15.8%5Y25.2%-41.0%
5Y25.2%10Y3.3%+21.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-13.5%-12.7%-0.8%
TTM-15.8%-13.0%-2.8%
YOY177.5%-12.3%+189.8%
5Y25.2%-13.6%+38.8%
10Y3.3%-15.7%+19.0%
4.3.1.3. Return on Equity

Shows how efficient Capricor is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Capricor to the Biotechnology industry mean.
  • -18.4% Return on Equity means Capricor generated $-0.18 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Capricor Therapeutics Inc:

  • The MRQ is -18.4%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -42.6%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-18.4%TTM-42.6%+24.2%
TTM-42.6%YOY1,562.2%-1,604.8%
TTM-42.6%5Y291.4%-334.1%
5Y291.4%10Y-139.8%+431.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-18.4%-16.8%-1.6%
TTM-42.6%-17.7%-24.9%
YOY1,562.2%-16.2%+1,578.4%
5Y291.4%-20.3%+311.7%
10Y-139.8%-21.2%-118.6%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Capricor Therapeutics Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Capricor is operating .

  • Measures how much profit Capricor makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Capricor to the Biotechnology industry mean.
  • An Operating Margin of -575.2% means the company generated $-5.75  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Capricor Therapeutics Inc:

  • The MRQ is -575.2%. The company is operating very inefficient. -2
  • The TTM is -271.7%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-575.2%TTM-271.7%-303.5%
TTM-271.7%YOY-356.3%+84.6%
TTM-271.7%5Y-2,901.5%+2,629.8%
5Y-2,901.5%10Y-1,776.4%-1,125.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-575.2%-202.6%-372.6%
TTM-271.7%-321.1%+49.4%
YOY-356.3%-227.9%-128.4%
5Y-2,901.5%-371.8%-2,529.7%
10Y-1,776.4%-506.0%-1,270.4%
4.3.2.2. Operating Ratio

Measures how efficient Capricor is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of -997.47 means that the operating costs are $-997.47 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Capricor Therapeutics Inc:

  • The MRQ is -997.469.
  • The TTM is -247.374.
Trends
Current periodCompared to+/- 
MRQ-997.469TTM-247.374-750.095
TTM-247.374YOY5.281-252.654
TTM-247.3745Y-20.436-226.938
5Y-20.43610Y-3.503-16.933
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-997.4692.171-999.640
TTM-247.3743.241-250.615
YOY5.2813.257+2.024
5Y-20.4364.839-25.275
10Y-3.5036.440-9.943
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Capricor Therapeutics Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Capricor is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 0.00 means the company has $0.00 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Capricor Therapeutics Inc:

  • The MRQ is 0.004. The company is unable to pay all its short-term debts. -2
  • The TTM is 1.143. The company is just able to pay all its short-term debts.
Trends
Current periodCompared to+/- 
MRQ0.004TTM1.143-1.139
TTM1.143YOY1.269-0.126
TTM1.1435Y6.589-5.446
5Y6.58910Y5.471+1.118
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0043.626-3.622
TTM1.1433.858-2.715
YOY1.2694.600-3.331
5Y6.5895.917+0.672
10Y5.4716.136-0.665
4.4.3.2. Quick Ratio

Measures if Capricor is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Capricor to the Biotechnology industry mean.
  • A Quick Ratio of 0.00 means the company can pay off $0.00 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Capricor Therapeutics Inc:

  • The MRQ is 0.005. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 1.843. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ0.005TTM1.843-1.838
TTM1.843YOY1.895-0.052
TTM1.8435Y7.520-5.677
5Y7.52010Y6.729+0.791
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0053.022-3.017
TTM1.8433.369-1.526
YOY1.8954.337-2.442
5Y7.5205.931+1.589
10Y6.7296.457+0.272
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Capricor Therapeutics Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Capricor assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Capricor to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.27 means that Capricor assets are financed with 26.6% credit (debt) and the remaining percentage (100% - 26.6%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Capricor Therapeutics Inc:

  • The MRQ is 0.266. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.552. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.266TTM0.552-0.286
TTM0.552YOY0.910-0.358
TTM0.5525Y0.489+0.063
5Y0.48910Y0.683-0.194
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2660.341-0.075
TTM0.5520.342+0.210
YOY0.9100.314+0.596
5Y0.4890.365+0.124
10Y0.6830.385+0.298
4.5.4.2. Debt to Equity Ratio

Measures if Capricor is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Capricor to the Biotechnology industry mean.
  • A Debt to Equity ratio of 36.2% means that company has $0.36 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Capricor Therapeutics Inc:

  • The MRQ is 0.362. The company is very able to pay all its debts with equity. +2
  • The TTM is 1.493. The company is able to pay all its debts with equity. +1
Trends
Current periodCompared to+/- 
MRQ0.362TTM1.493-1.131
TTM1.493YOY6.694-5.201
TTM1.4935Y2.078-0.586
5Y2.07810Y14.067-11.989
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3620.390-0.028
TTM1.4930.429+1.064
YOY6.6940.383+6.311
5Y2.0780.441+1.637
10Y14.0670.493+13.574
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Capricor generates.

  • Above 15 is considered overpriced but always compare Capricor to the Biotechnology industry mean.
  • A PE ratio of -13.77 means the investor is paying $-13.77 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Capricor Therapeutics Inc:

  • The EOD is -13.154. Based on the earnings, the company is expensive. -2
  • The MRQ is -13.769. Based on the earnings, the company is expensive. -2
  • The TTM is -24.880. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-13.154MRQ-13.769+0.616
MRQ-13.769TTM-24.880+11.111
TTM-24.880YOY-6.329-18.551
TTM-24.8805Y-12.088-12.792
5Y-12.08810Y-11.248-0.840
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-13.154-2.195-10.959
MRQ-13.769-2.710-11.059
TTM-24.880-3.253-21.627
YOY-6.329-3.335-2.994
5Y-12.088-6.423-5.665
10Y-11.248-6.851-4.397
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Capricor Therapeutics Inc:

  • The EOD is -14.115. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -14.776. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -15.901. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-14.115MRQ-14.776+0.661
MRQ-14.776TTM-15.901+1.126
TTM-15.901YOY-0.597-15.305
TTM-15.9015Y-9.965-5.937
5Y-9.96510Y-11.051+1.086
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-14.115-3.003-11.112
MRQ-14.776-3.732-11.044
TTM-15.901-4.078-11.823
YOY-0.597-4.504+3.907
5Y-9.965-8.328-1.637
10Y-11.051-9.433-1.618
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Capricor is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 10.13 means the investor is paying $10.13 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Capricor Therapeutics Inc:

  • The EOD is 9.678. Based on the equity, the company is overpriced. -1
  • The MRQ is 10.131. Based on the equity, the company is expensive. -2
  • The TTM is 13.893. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD9.678MRQ10.131-0.453
MRQ10.131TTM13.893-3.762
TTM13.893YOY9.600+4.293
TTM13.8935Y9.135+4.758
5Y9.13510Y78.382-69.247
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD9.6781.902+7.776
MRQ10.1312.272+7.859
TTM13.8932.473+11.420
YOY9.6002.459+7.141
5Y9.1353.688+5.447
10Y78.3824.241+74.141
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Capricor Therapeutics Inc.

4.8.1. Institutions holding Capricor Therapeutics Inc

Institutions are holding 18.581% of the shares of Capricor Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-09-30Vanguard Group Inc3.46720.00041576541276001.7819
2024-09-30Geode Capital Management, LLC1.40350.0008638189-3384-0.5275
2024-09-30Northern Trust Corp0.58960.0007268071138458106.8242
2024-09-30Point72 Asset Management, L.P.0.55030.00972502042502040
2024-09-30Advisor Group Holdings, Inc.0.52950.00832407507845048.3364
2024-09-30Ghost Tree Capital, LLC0.27490.57431250001250000
2024-09-30StemPoint Capital LP0.20590.426493638936380
2024-09-30UBS O'Connor LLC0.18230.097382900829000
2024-09-30Wells Fargo & Co0.09710.000244132-814-1.8111
2024-09-30AQR Capital Management LLC USD0.08710.000839616396160
2024-09-30AQR Capital Management LLC USD0.08710.000839616396160
Total 7.47451.11973398657+871284+25.6%

4.9.2. Funds holding Capricor Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-12-31SPDR® S&P Biotech ETF3.14540.31171430193-25450-1.7484
2024-11-30Vanguard Total Stock Mkt Idx Inv2.4910.0012113267600
2024-12-31iShares Russell 2000 ETF2.17820.019990448-3800-0.3822
2024-11-30Vanguard Institutional Extnd Mkt Idx Tr1.00720.007245798824550.5389
2024-12-31iShares Russell 2000 Growth ETF0.62490.031128412400
2024-10-31Fidelity Small Cap Index0.57810.0197262854-188-0.0715
2024-12-31State St Russell Sm/Mid Cp® Indx NL Cl C0.51830.00722356866640039.2236
2024-11-30Fidelity Extended Market Index0.36580.007116633112220.7401
2024-12-30Direxion Daily S&P Biotech Bull 3X ETF0.30960.2418140774-1082-0.7627
2024-11-30Vanguard Russell 2000 ETF0.26620.016612105355704.8232
2024-12-31State St Russell Sm Cap® Indx SL Cl I0.19350.01288800000
2024-12-31Extended Equity Market Fund K0.18910.008859721436420.0592
2024-12-31iShares Micro-Cap ETF0.18460.12118394000
2024-11-30Schwab Small Cap Index0.13620.01676191800
2024-12-31Russell 2500™ Index Fund F0.13420.0079610321909245.5222
2024-11-30SPDR® Russell 2000 US Small Cap ETF0.13230.0241601341254926.3718
2024-09-30NT R2000 Index Fund - NL0.13040.013759293592930
2024-12-31iShares Core S&P Total US Stock Mkt ETF0.12710.00125780100
2024-12-31iShares Russell 2000 Value ETF0.12180.006255379-1554-2.7295
2024-09-30NT R2000 Growth Index Fund - NL0.12150.02455227552270
Total 12.95540.89835890823+204098+3.5%

5.3. Insider Transactions

Insiders are holding 16.747% of the shares of Capricor Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-09-20Shinyaku Co Ltd NipponBUY27985075.36
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2023-09-302023-12-312024-03-312024-06-302024-09-30
Cost of Revenue  276313082433126357-2,259,737-2,259,380



5.2. Latest Balance Sheet

Balance Sheet of 2024-09-30. Currency in USD. All numbers in thousands.

Summary
Total Assets92,952
Total Liabilities24,687
Total Stockholder Equity68,265
 As reported
Total Liabilities 24,687
Total Stockholder Equity+ 68,265
Total Assets = 92,952

Assets

Total Assets92,952
Total Current Assets85,823
Long-term Assets7,128
Total Current Assets
Cash And Cash Equivalents 68,377
Short-term Investments 16,651
Net Receivables 410
Total Current Assets  (as reported)85,823
Total Current Assets  (calculated)85,438
+/- 385
Long-term Assets
Property Plant Equipment 6,809
Long-term Assets Other 319
Long-term Assets  (as reported)7,128
Long-term Assets  (calculated)7,128
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities20,475,506
Long-term Liabilities4,211
Total Stockholder Equity68,265
Total Current Liabilities
Short-term Debt 814
Other Current Liabilities 20,461,562
Total Current Liabilities  (as reported)20,475,506
Total Current Liabilities  (calculated)20,462,375
+/- 13,131
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt835
Long-term Liabilities Other 3,376
Long-term Liabilities  (as reported)4,211
Long-term Liabilities  (calculated)4,211
+/-0
Total Stockholder Equity
Common Stock40
Retained Earnings -192,718
Accumulated Other Comprehensive Income 96
Other Stockholders Equity 260,846
Total Stockholder Equity (as reported)68,265
Total Stockholder Equity (calculated)68,265
+/-0
Other
Capital Stock40
Cash and Short Term Investments 85,029
Common Stock Shares Outstanding 33,090
Current Deferred Revenue13,131
Liabilities and Stockholders Equity 92,952
Net Debt -66,729
Net Invested Capital 68,265
Net Working Capital 65,348
Property Plant and Equipment Gross 10,049
Short Long Term Debt Total 1,649



5.3. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-302007-06-302007-03-312006-12-312006-09-302006-06-302006-03-312005-12-312005-09-302005-06-302005-03-312004-12-312004-09-302004-06-302004-03-312003-12-312003-09-302003-06-302003-03-312002-12-312002-09-302002-06-302002-03-312001-12-312001-09-302001-06-302001-03-31
> Total Assets 
0
0
0
0
0
0
0
0
0
0
0
1
9
4
1
1
3
0
3
0
0
1
0
4
0
0
18,623
17,089
14,487
11,190
8,409
6,435
4,263
2,254
4,829
3,620
2,372
5,872
4,809
3,666
2,418
3,704
3,091
1,372
1,372
1,000
495
227
495
295
114
5,538
15,977
18,437
16,283
13,632
27,471
23,691
19,882
16,070
16,985
13,892
24,472
18,747
14,068
14,218
15,794
16,274
15,388
14,327
12,233
9,247
8,618
7,307
7,907
11,114
14,294
37,126
36,187
34,619
43,544
39,930
43,101
41,330
64,922
58,066
53,928
50,095
53,863
46,011
37,152
58,734
49,444
38,277
92,952
92,95238,27749,44458,73437,15246,01153,86350,09553,92858,06664,92241,33043,10139,93043,54434,61936,18737,12614,29411,1147,9077,3078,6189,24712,23314,32715,38816,27415,79414,21814,06818,74724,47213,89216,98516,07019,88223,69127,47113,63216,28318,43715,9775,5381142954952274951,0001,3721,3723,0913,7042,4183,6664,8095,8722,3723,6204,8292,2544,2636,4358,40911,19014,48717,08918,62300401003031149100000000000
   > Total Current Assets 
0
0
0
0
0
0
0
0
0
0
0
1
9
4
1
1
3
0
3
0
0
1
0
4
0
0
18,408
16,760
14,044
10,764
8,005
6,046
3,946
1,956
4,556
3,433
2,296
5,801
4,740
3,597
2,352
3,640
3,028
1,310
1,310
942
438
172
438
289
109
3,681
14,031
16,410
14,196
11,608
25,420
21,643
17,714
13,990
14,890
11,809
22,404
18,108
13,465
13,640
15,232
14,125
13,165
13,541
11,393
8,471
7,904
6,643
6,828
9,885
13,770
36,253
35,491
33,677
41,880
38,731
41,298
36,437
59,634
52,624
47,505
42,889
46,595
38,924,873
29,527
50,855
41,412
30,669
85,823
85,82330,66941,41250,85529,52738,924,87346,59542,88947,50552,62459,63436,43741,29838,73141,88033,67735,49136,25313,7709,8856,8286,6437,9048,47111,39313,54113,16514,12515,23213,64013,46518,10822,40411,80914,89013,99017,71421,64325,42011,60814,19616,41014,0313,6811092894381724389421,3101,3103,0283,6402,3523,5974,7405,8012,2963,4334,5561,9563,9466,0468,00510,76414,04416,76018,40800401003031149100000000000
       Cash And Cash Equivalents 
0
0
0
0
0
0
0
0
0
0
0
1
9
4
1
1
3
0
3
0
0
1
0
4
0
0
18,039
16,233
13,660
10,348
7,364
5,501
3,607
1,770
4,224
3,176
2,013
5,563
4,436
3,378
2,124
3,260
2,607
1,039
1,039
777
283
47
283
229
71
1,730
12,979
11,582
9,805
8,035
6,939
20,533
17,218
5,568
11,766
8,851
20,521
16,195
2,750
12,259
13,895
14,125
13,165
12,334
4,378
4,259
7,170
5,891
6,828
3,899
13,217
36,253
35,300
32,666
41,880
38,078
40,839
34,885
58,334
16,394
8,414
9,603
10,606
9,837,133
8,985
14,695
6,215
10,688
68,377
68,37710,6886,21514,6958,9859,837,13310,6069,6038,41416,39458,33434,88540,83938,07841,88032,66635,30036,25313,2173,8996,8285,8917,1704,2594,37812,33413,16514,12513,89512,2592,75016,19520,5218,85111,7665,56817,21820,5336,9398,0359,80511,58212,9791,73071229283472837771,0391,0392,6073,2602,1243,3784,4365,5632,0133,1764,2241,7703,6075,5017,36410,34813,66016,23318,03900401003031149100000000000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
326
326
326
325
2,977
15,484
15,494
12,999
7,999
2,498
2,500
2,500
12,991
8,993
3,999
4,998
7,985
5,995
5,995
5,994
2,997
2,997
0
0
5,986
5,986
0
0
0
0
0
0
0
0
35,023
38,200
31,818
34,566
27,956,325
19,537
24,793
33,702
18,774
16,651
16,65118,77433,70224,79319,53727,956,32534,56631,81838,20035,023000000005,9865,986002,9972,9975,9945,9955,9957,9854,9983,9998,99312,9912,5002,5002,4987,99912,99915,49415,4842,977325326326326000000000000000000000000000000000000000000000000000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
261
360
746
380
403
212
304
218
1,163
223
197
313
537
345
307
287
173
205
123
144
101
88
119
50
17
56
0
0
180
392
357
548
548
548
548
547,580
548
10,372
369
370
410
41037036910,372548547,58054854854854835739218000561750119881011441232051732873073455373131972231,163218304212403380746360261010000000000000000000000000000000000000000000000000000
       Other Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
369
526
385
416
641
545
339
185
332
258
283
237
304
219
228
380
421
271
271
165
156
125
156
60
38
223
170
123
105
236
203
131
92
211
321
239
118
343
398
239
190
501
522
388
426
724
611
608
129
571
434
250
174
1,011
736
653
279
1,160
943
659
344
920
875
583,835
458
996
1,126
837
385,065
385,0658371,126996458583,8358759203446599431,1602796537361,01117425043457112960861172442638852250119023939834311823932121192131203236105123170223386015612515616527127142138022821930423728325833218533954564141638552636900000000000000000000000000
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
215
330
443
426
404
390
317
298
273
186
75
72
69
69
67
65
63
62
62
58
57
55
57
6
5
1,857
1,946
2,028
2,087
2,025
2,051
2,048
2,169
2,080
2,095
2,083
2,067
639
603
578
561
2,149
2,224
786
840
776
713
664
1,080
1,228
524
873
696
942
1,665
1,199
1,802
4,893
5,288
5,442
6,423
7,206
7,269
7,086,325
7,625
7,879
8,033
7,608
7,128
7,1287,6088,0337,8797,6257,086,3257,2697,2066,4235,4425,2884,8931,8021,1991,6659426968735241,2281,0806647137768407862,2242,1495615786036392,0672,0832,0952,0802,1692,0482,0512,0252,0872,0281,9461,857565755575862626365676969727518627329831739040442644333021500000000000000000000000000
       Property Plant Equipment 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
58
63
88
86
80
74
66
60
32
27
23
20
17
17
15
13
11
10
10
6
5
3
5
1
1
74
164
204
225
229
254
263
332
319
345
355
352
435
412
399
394
372
535
507
622
574
542
507
475
443
411
487
604
851
839
1,110
1,514
4,618
5,012
5,174
6,155
6,938
7,001
6,818,153
7,357
7,611
7,739
7,289
6,809
6,8097,2897,7397,6117,3576,818,1537,0016,9386,1555,1745,0124,6181,5141,110839851604487411443475507542574622507535372394399412435352355345319332263254229225204164741153561010111315171720232732606674808688635800000000000000000000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
20
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000000000000000002000000000000000000000000000000000000000000000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
127
253
236
234
218
210
144
131
133
107
107
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,757
1,756
1,769
1,807
1,740
1,728
1,715
1,703
1,691
1,679
1,667
1,654
142
130
118
106
93
82
71,410
61
50
39
28
17,314
6,495
5,413
4,330
3
2
1,083
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000001,083234,3305,4136,49517,3142839506171,41082931061181301421,6541,6671,6791,6911,7031,7151,7281,7401,8071,7691,7561,7570000000000000010710713313114421021823423625312700000000000000000000000000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
52
52
0
52
0
0
0
0
0
0
1,783
1,782
1,824
1,862
1,795
1,797
1,785
1,836
1,761
1,750
1,728
1,716
204
191
179
168
189
158
207
157
152
133
129
125
120
107
82
89
89
89
89
289
276
276
58,066
0
268
0
-45,965,187
0
0
0
0
-92,858,661
-92,858,6610000-45,965,1870268058,06627627628989898989821071201251291331521572071581891681791912041,7161,7281,7501,7611,8361,7851,7971,7951,8621,8241,7821,783000000520525200000000000000000000000000000000000000000
> Total Liabilities 
0
0
0
9
9
12
21
25
25
35
35
42
52
50
50
59
67
67
74
78
83
90
125
135
145
168
1,357
1,889
1,379
1,000
918
1,332
778
440
845
638
889
1,150
1,505
1,069
744
436
718
541
541
458
468
394
468
1,528
1,682
6,073
17,636
21,522
20,755
19,881
20,147
19,136
17,957
17,101
18,068
19,008
24,423
22,751
21,260
20,805
20,064
5,047
4,854
4,696
5,252
4,631
4,877
4,943
4,337
4,274
4,701
5,472
5,779
6,419
7,164
6,550
6,365
9,962
40,279
39,337
38,502
38,309
47,657
43,280
38,940
36,133
31,010
26,775
24,687
24,68726,77531,01036,13338,94043,28047,65738,30938,50239,33740,2799,9626,3656,5507,1646,4195,7795,4724,7014,2744,3374,9434,8774,6315,2524,6964,8545,04720,06420,80521,26022,75124,42319,00818,06817,10117,95719,13620,14719,88120,75521,52217,6366,0731,6821,5284683944684585415417184367441,0691,5051,1508896388454407781,3329181,0001,3791,8891,357168145135125908378746767595050524235352525211299000
   > Total Current Liabilities 
0
0
0
9
9
12
21
25
25
35
35
42
52
50
50
59
67
67
74
78
83
90
125
135
145
168
1,357
1,889
1,311
1,000
918
1,332
778
440
845
638
889
1,150
1,505
1,069
744
436
718
541
541
267
287
331
287
1,016
1,182
2,053
6,299
6,492
6,192
6,300
7,545
6,863
6,534
6,529
7,341
6,205
6,670
4,895
3,299
16,644
16,688
1,671
1,478
1,320
1,876
1,255
1,501
1,567
961
898
1,325
1,918
2,278
2,971
3,752
3,174
2,988
4,133
14,323
19,547
23,195
23,587
37,132
35,153,674
32,927
31,270
26,384
22,355
20,475,506
20,475,50622,35526,38431,27032,92735,153,67437,13223,58723,19519,54714,3234,1332,9883,1743,7522,9712,2781,9181,3258989611,5671,5011,2551,8761,3201,4781,67116,68816,6443,2994,8956,6706,2057,3416,5296,5346,8637,5456,3006,1926,4926,2992,0531,1821,0162873312872675415417184367441,0691,5051,1508896388454407781,3329181,0001,3111,8891,357168145135125908378746767595050524235352525211299000
       Short-term Debt 
0
0
0
0
0
2
6
8
8
29
32
37
47
47
48
52
62
63
69
69
75
77
125
125
132
166
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
191
259
327
0
0
0
0
9,156
0
2,734
1,823
9,156
0
0
699
13,906
13,906
14,156
14,156
0
0
0
0
0
0
0
0
0
0
140
193
247
283
0
0
418
498
580
698
682
694
707,425
730
749
772
793
814
814793772749730707,42569468269858049841800283247193140000000000014,15614,15613,90613,906699009,1561,8232,73409,1560000327259191000000000000000000000016613212512577756969636252484747373229886200000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
9,156
0
0
0
9,156
0
0
0
13,906
13,906
14,156
14,156
0
0
0
0
0
0
0
0
0
0
140
193
247
283
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000283247193140000000000014,15614,15613,90613,9060009,1560009,1560000000000000000000000000000000000000000000000000000000
       Accounts payable 
0
0
0
0
8
9
8
9
9
5
3
5
5
3
3
7
5
4
5
8
8
13
0
9
11
0
573
659
816
696
559
746
456
281
306
235
165
154
592
332
479
238
504
541
438
122
287
331
210
398
339
1,507
1,519
1,683
1,914
1,699
2,746
2,679
2,309
2,531
3,224
2,924
3,920
3,039
2,506
2,177
1,264
1,496
1,478
1,320
1,876
1,255
1,501
1,567
961
898
1,325
1,778
2,085
2,725
3,469
2,782
2,459
3,116
3,524
3,128
3,937
4,835
5,426
5,134
-6,785,158
6,223
6,239
6,160
0
06,1606,2396,223-6,785,1585,1345,4264,8353,9373,1283,5243,1162,4592,7823,4692,7252,0851,7781,3258989611,5671,5011,2551,8761,3201,4781,4961,2642,1772,5063,0393,9202,9243,2242,5312,3092,6792,7461,6991,9141,6831,5191,5073393982103312871224385415042384793325921541652353062814567465596968166595730119013885457335535998980000
       Other Current Liabilities 
0
0
0
0
1
1
7
7
7
1
1
0
0
0
0
0
0
0
0
0
0
0
124,968
1
2
2
784
1,231
495
304
360
586
322
160
539
403
725
996
913
737
265
199
213
0
104
145
0
0
77
359
516
546
614
642
112
434
633
539
580
352
471
547
3,920
489
110
311
1,268
174
0
0
0
0
1,501
1,567
0
0
1,325
1,778
2,277,960
2,971,282
3,469
3,174
2,988
3,716
4,098
94
3,937
89
5,426
5,128,676
6,791,950
27
10
10
20,461,562
20,461,5621010276,791,9505,128,6765,426893,937944,0983,7162,9883,1743,4692,971,2822,277,9601,7781,325001,5671,50100001741,2683111104893,920547471352580539633434112642614546516359770014510402131992657379139967254035391603225863603044951,231784221124,9680000000000011777110000
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
68
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
191
181
63
181
512
500
4,020
11,337
15,030
14,562
13,581
12,601
12,272
11,422
10,573
10,727
12,804
17,752
17,855
17,961
4,160
3,376
3,376
3,376
3,376
3,376
3,376
3,376
3,376
3,376
3,376
3,376
3,554
3,501
3,448
3,412
3,376
3,376
5,829
25,956
19,789
15,307
14,722
10,525
8,126,361
6,013
4,863
4,626
4,420
4,211
4,2114,4204,6264,8636,0138,126,36110,52514,72215,30719,78925,9565,8293,3763,3763,4123,4483,5013,5543,3763,3763,3763,3763,3763,3763,3763,3763,3763,3763,3764,16017,96117,85517,75212,80410,72710,57311,42212,27212,60113,58114,56215,03011,3374,020500512181631811910000000000000000680000000000000000000000000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
8,642
9,156
9,156
9,156
9,156
9,156
9,156
10,156
12,156
17,006
17,006
17,006
0
0
3,376
3,376
3,376
3,376
3,376
3,376
3,376
3,376
3,376
3,376
3,554
3,501
3,448
3,412
3,376
0
3,376
0
3,376
3,376
3,376
3,376
3,376
0
0
0
0
0
000003,3763,3763,3763,3763,37603,37603,3763,4123,4483,5013,5543,3763,3763,3763,3763,3763,3763,3763,3763,3763,3760017,00617,00617,00612,15610,1569,1569,1569,1569,1569,1569,1568,64200000000000000000000000000000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
58
7,375
6,388
5,407
4,426
3,444
3,116
2,267
1,417
571
647
3,847
3,949
4,055
4,160
3,377
3,376
3,376
3,376
3,376
3,376
3,376
3,376
3,376
3,376
3,376
3,376
3,376
3,376
3,376
3,376
3,376
3,376
23,650
17,631
0
12,844
0
6,608
0
0
0
0
0
000006,608012,844017,63123,6503,3763,3763,3763,3763,3763,3763,3763,3763,3763,3763,3763,3763,3763,3763,3763,3763,3763,3774,1604,0553,9493,8476475711,4172,2673,1163,4444,4265,4076,3887,37558000000000000000000000000000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
6,250
5,208
4,167
3,125
2,734
1,823
911
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000000000009111,8232,7343,1254,1675,2086,25000000000000000000000000000000000000000000000000000000
> Total Stockholder Equity
0
0
0
0
-9
-12
-21
-25
-25
-35
-35
-41
-43
-46
-49
-59
-64
-67
-71
-78
-83
-90
-125
-135
-145
-168
17,266
15,200
13,108
10,190
7,491
5,104
3,484
1,814
3,984
2,982
1,483
4,723
3,304
2,597
1,674
3,268
2,373
831
831
542
27
-167
27
-1,233
-1,568
-535
-1,659
-3,085
-4,472
-6,249
7,325
4,555
1,926
-1,032
-1,083
-5,116
49
-4,003
-7,192
-6,586
-4,271
11,227
10,534
9,631
6,980
4,616
3,740
2,364
3,570
6,839
9,593
31,654
30,408
28,200
36,381
33,380
36,736
31,368
24,643
18,729
15,426
11,786
6,206
2,731
-1,788
22,601
18,435
11,502
68,265
68,26511,50218,43522,601-1,7882,7316,20611,78615,42618,72924,64331,36836,73633,38036,38128,20030,40831,6549,5936,8393,5702,3643,7404,6166,9809,63110,53411,227-4,271-6,586-7,192-4,00349-5,116-1,083-1,0321,9264,5557,325-6,249-4,472-3,085-1,659-535-1,568-1,23327-167275428318312,3733,2681,6742,5973,3044,7231,4832,9823,9841,8143,4845,1047,49110,19013,10815,20017,266-168-145-135-125-90-83-78-71-67-64-59-49-46-43-41-35-35-25-25-21-12-90000
   Common Stock
0
0
0
0
8
8
8
8
8
8
8
8
8
8
8
8
8
8
8
8
8
8
8
8
1
1
24
24
24
24
24
24
24
24
27
27
27
35
35
35
35
40
40
40
40
43
43
43
43
43
44
12
12
12
12
12
16
16
16
16
18
18
21
21
21
23
25
26
28
30
31
31
34
3
4
5
9
20
20
21
23
23
24
24
24
24
25
25
25
25,764
26
31
32
32
40
403232312625,7642525252424242423232120209543343131302826252321212118181616161612121212124443434343434040404035353535272727242424242424242411888888888888888888880000
   Retained Earnings Total Equity00000-152,215-144,848-137,080-129,359-122,9880-108,0600-97,938-93,190-88,038-83,860-79,950-76,466-74,381-72,911-71,305-69,258-66,739-63,479-59,343-55,219-51,548-63,853-61,118-57,646-53,979-49,461-44,128-39,439-35,172-31,826-28,914-25,791-22,315-20,387-18,843-17,309-16,099-48,137-47,788-47,191-46,708-46,506-45,940-45,587-44,815-43,151-42,00700000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-8
-14
-14
-14
-14
-34
-34
0
0
-39
-39
0
0
-52
-52
0
0
-41
-41
0
0
-47
-47
-47
0
-1
0
-1
-2
-112
-4
7
12
9
3
5
1
4
10
7
9
12
20
18
20
12
-489
-518
-550
-1
-611
-642
-678
0
0
0
0
0
0
23
122
105
95
179,693
113
236
308
155
96
96155308236113179,6939510512223000000-678-642-611-1-550-518-4891220182012971041539127-4-112-2-10-10-47-47-4700-41-4100-52-5200-39-3900-34-34-14-14-14-14-800000000000000000000000000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
45,235
45,484
45,606
45,778
46,439
46,490
46,498
46,505
46,512
46,526
15,553
15,638
15,748
15,905
16,055
33,104
33,447
33,724
34,115
38,335
38,989
49,488
49,951
50,423
54,502
59,549
62,737
65,705
68,925
70,409
71,311
72,965
73,665
76,478
81,216
86,049
111,584
114,248
116,217
129,548
131,295
0
139,404
0
141,670
144,638
148,735
150,934
154,740
0
0
0
0
0
00000154,740150,934148,735144,638141,6700139,4040131,295129,548116,217114,248111,58486,04981,21676,47873,66572,96571,31170,40968,92565,70562,73759,54954,50250,42349,95149,48838,98938,33534,11533,72433,44733,10416,05515,90515,74815,63815,55346,52646,51246,50546,49846,49046,43945,77845,60645,48445,23500000000000000000000000000000000000000000
   Treasury Stock00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
43
43
43
43
43
43
43
43
43
43
43
43
43
43
43
43
45
47
47
47
54
54
27,628
28,085
29,052
29,911
30,532
31,140
31,265
32,095
36,290
36,893
37,286
42,013
42,404
42,545
42,766
45,235
45,484
0
45,647
46,439
0
0
46,490
46,512
46,526
15,553
15,638
15,748
15,905
16,055
33,104
33,447
33,724
34,115
38,335
38,989
49,488
49,951
50,423
54,502
59,549
62,737
65,705
68,925
70,409
71,311
72,965
73,665
76,478
81,216
86,049
111,584
114,248
116,217
129,548
131,295
138,582
139,404
140,497
141,670
144,638
148,735
150,934
152,011,930
156,679
181,702
187,257
191,477
260,846
260,846191,477187,257181,702156,679152,011,930150,934148,735144,638141,670140,497139,404138,582131,295129,548116,217114,248111,58486,04981,21676,47873,66572,96571,31170,40968,92565,70562,73759,54954,50250,42349,95149,48838,98938,33534,11533,72433,44733,10416,05515,90515,74815,63815,55346,52646,51246,4900046,43945,647045,48445,23542,76642,54542,40442,01337,28636,89336,29032,09531,26531,14030,53229,91129,05228,08527,628545447474745434343434343434343434343434343430000



5.4. Balance Sheets

Currency in USD. All numbers in thousands.